Rein Therapeutics gets FDA OK to resume Phase 2 LTI-03 trial

Rein Therapeutics announced FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis.

Rhea-AI Filing Summary

Rein Therapeutics announced FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report. No financial terms or operational details were provided in this excerpt.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RNTX announce in this 8-K?

The company reported FDA clearance to resume its U.S. Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.

Which program is affected for RNTX?

The clearance pertains to LTI-03, a candidate being studied for idiopathic pulmonary fibrosis.

What stage is the clinical study?

It is a Phase 2 trial in the United States.

Where can I read more details?

Additional information is in the company’s press release attached as Exhibit 99.1.

Does the filing include financial data or terms?

This excerpt provides no financial terms or metrics related to the update.

When was the clearance announced?

The company announced the update on November 3, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/03/2025 - 07:45 AM EST Learn about SEC filing dates

NASDAQ false 0001420565 0001420565 2025-11-03 2025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 3, 2025

REIN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-38130		13-4196017
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

12407 N. Mopac Expy., Suite 250, #390

Austin, Texas 78758

(Address of principal executive offices)

(737) 802-1989

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock: Par value $.001		RNTX		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 3, 2025, Rein Therapeutics, Inc. (“Company”) issued a press release concerning FDA clearance for the Company to resume its U.S. Phase 2 Trial of LTI-03 in idiopathic pulmonary fibrosis. A copy of the press release is attached as Exhibit 99.1 hereto.

Item 9.01  Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed with this report:

Exhibit 99.1		The Company’s press release dated November 3, 2025
Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				REIN THERAPEUTICS, INC.
Dated: November 3, 2025						/s/ Brian Windsor
						Brian Windsor, Ph.D.,
						President and Chief Executive Officer